Health Care · Biological Products, (No Diagnostic Substances)

SANA Sana Biotechnology, Inc. SEC Filings & Insider Trading Activity 2026

company
CIK 177012168 filings
Russell 2000

SANA at a glance

Sana Biotechnology, Inc. (SANA, SEC CIK 1770121) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and Form 4 insider filings as recently as October 6, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • As of September 30, 2026, 29 institutional investment managers tracked by SignalX reported holding Sana Biotechnology, Inc. (SANA) shares worth $179.7 million in 13F-HR filings.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
29 funds
$179.7M · −3 vs prior quarter
Latest 8-K
Nov 5, 2026
Item 2.02

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no products approved for sale
  • Net income $20.4M vs net loss $42.2M YoY, driven by $63.4M contingent consideration gain
  • R&D expense $33.9M, up $3.8M YoY, driven by SC451 and SG293 manufacturing costs
  • Cash, equivalents and securities $121.7M; nine-month operating cash use $108.9M
  • Outlook: additional capital needed within 12 months, substantial going-concern doubt, SC451 and SG293 prioritized

Risk Factors

  • New H-1B visa risk, triggered by a new one-time $100,000 fee for new petitions and proposed program reforms
  • Portfolio prioritization risk, November 2025 suspension of SC291 and SC262 development reduced pipeline breadth and increased reliance on SC451 and SG293
  • Regulatory risk, FDA boxed-warning scrutiny for CAR T malignancies could impose additional requirements on in vivo CAR T programs
  • Operational risk, limited NHP model availability has delayed preclinical studies and increased costs
  • Financial risk, substantial losses and going-concern uncertainty create dependence on additional capital for operations

AI summary of the SANA 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 5, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results announced for quarter ended September 30, 2026
  • Detailed results and management commentary contained in Exhibit 99.1, the accompanying press release

Item EX-99.1: Item EX-99.1

  • Cash $121.7M at September 30, 2026, with runway into mid-2027, but nine-month non-GAAP operating cash burn reached $103.4M
  • SC451 IND and Phase 1/2 trial targeted as early as 2026, creating a near-term clinical catalyst in type 1 diabetes
Filed Sep 8, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • SC451 IND filing and Phase 1/2 initiation targeted for 2026, creating near-term clinical catalysts in type 1 diabetes
  • UP421 demonstrated hypoimmune islet-cell survival and function through 14 months without immunosuppression

Item 7.01: Regulation FD Disclosure

  • Updated corporate presentation released September 8, 2026 for investor-conference discussions
  • Exhibit 99.1 contains the presentation, potentially detailing updated strategy, pipeline, or clinical priorities
Filed Aug 10, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q2 net loss improved to $63.6M, or $0.22 per share, from $93.8M, benefiting from no 2025 impairment charge
  • Cash, equivalents, and marketable securities reached $160.5M, supported by $93.3M financing proceeds and providing runway into mid-2027

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 financial results announced for quarter ended June 30, 2026
  • Exhibit 99.1 contains Sana Biotechnology’s detailed earnings release for investor review

AI summaries of SANA 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for SANA

Don't miss the next SANA filing

  • Alerts as it files. A push when SANA files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut SANA, by share count.
  • Ask anything. An AI agent that reads every SANA filing and answers with sources.

SANA alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Bishop Hans EdgarAOct 5, 2026-
PATEL DHAVALKUMAR DHIRAJLALFAug 27, 2026$4.11
PATEL DHAVALKUMAR DHIRAJLALMAug 26, 2026-
PATEL DHAVALKUMAR DHIRAJLALMAug 26, 2026-
Bishop Hans EdgarAJul 6, 2026-
Rosiello Robert L.AJun 4, 2026-
REICIN ALISEAJun 4, 2026-
Yang Patrick YAJun 4, 2026-

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Operating Income-$293.1M-$272.7M-$250.3M
Net Income-$283.3M-$266.8M-$244.2M
Balance Sheet
Total Assets$565.3M$501.0M$416.9M
Equity$287.5M$250.5M$160.9M
ROE-98.5%-106.5%-151.8%
Per Share
EPS-$-1.16$-0.96
Cash Flow
Operating CF-$253.6M-$223.2M-$143.8M
CapEx$20.0M$33.4M$938K

Source: XBRL data in Sana Biotechnology, Inc. (SANA)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate SANA share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
SANA shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202629$179.7M
Q2 202632$348.7M
Q1 202630$275.7M
Q4 202527$368.8M
Q3 202526$332.0M
Q2 202528$210.9M
Q1 202524$102.3M
Q4 202420$98.3M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 216 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

SANA filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
8-KNov 5, 2026Analysis-
10-QNov 5, 2026Analysis
4Oct 6, 2026--
8-KSep 8, 2026Analysis-
4Aug 27, 2026--
10-QAug 10, 2026Analysis
8-KAug 10, 2026Analysis-
4Jul 7, 2026--
4Jun 5, 2026-
4Jun 5, 2026-
8-KJun 5, 2026Analysis
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
4Jun 5, 2026-
SC 13GMay 21, 2026-
8-KMay 15, 2026Analysis
8-KMay 11, 2026Analysis
10-QMay 11, 2026Analysis
8-KApr 24, 2026Analysis-
8-KApr 13, 2026Analysis-
4Apr 8, 2026--
4Mar 10, 2026--

Related Health Care companies

All Health Care →

SANA SEC filings: frequently asked questions

Which institutions hold SANA stock?

As of September 30, 2026, the largest Sana Biotechnology, Inc. (SANA) holders among the 13F filers tracked by SignalX were BlackRock ($47.8 million), State Street Corp ($27.9 million), Vanguard Capital Management LLC ($25.1 million), Bank of America Corp ($13.5 million), Marex Group plc ($11.6 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What did SANA report in its latest 8-K?

Sana Biotechnology, Inc. (SANA) filed an 8-K on November 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q3 2026 financial results announced for quarter ended September 30, 2026.

What are the latest SANA SEC filings?

Sana Biotechnology, Inc. (SANA) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on November 5, 2026, an 8-K current report on November 5, 2026 and a Form 4 insider filing on October 6, 2026.

What is SANA's SEC CIK number?

Sana Biotechnology, Inc. (SANA)'s SEC Central Index Key (CIK) is 1770121. EDGAR lists every SANA filing under that number.

Ask anything about SANA

The research agent reads SANA's filings, financials, insider trades and 13F holders, then answers with sources.